EurekaMag
+ Translate
+ Most Popular
The pigeon tick (Argas reflexus): its biology, ecology, and epidemiological aspects
Prevalence of hemoglobin abnormalities in Kebili (Tunisian South)
Lipogranuloma: a preventable complication of dacryocystorhinostomy
Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency
Bees from the Belgian Congo. The acraensis group of Anthophora
Placing gingival retraction cord
Total serum IgE, allergy skin testing, and the radioallergosorbent test for the diagnosis of allergy in asthmatic children
Acariens plumicoles Analgesoidea parasites des oiseaux du Maroc
Injuries of terminal phalanges of the fingers in children
Biology of flowering and nectar production in pear (Pyrus communis)
Das Reliktvorkommen der Aspisviper (Vipera aspis L.) im Schwarzwald
Hydrological modelling of drained blanket peatland
Pathologic morphology and clinical significance of the anomalous origin of the left circumflex coronary artery from the right coronary artery. General review and autopsy analysis of 30 cases
Cyto genetic analyses of lymphocyte cultures after exposure to calcium cyclamate
Axelrodia riesei, a new characoid fish from Upper Rio Meta in Colombia With remarks concerning the genus Axelrodia and description of a similar, sympatric, Hyphessobrycon-species
Favorable evolution of a case of tuberculosis of pancreas under antibiotic action
RIFM fragrance ingredient safety assessment, Valencene, CAS Registry Number 4630-07-3
Parenteral microemulsions: an overview
Temperate pasture: management for grazing and conservation
Evaluation of a new coprocessed compound based on lactose and maize starch for tablet formulation
Thermal expansion and cracking of three confined water-saturated igneous rocks to 800C
Revision of the genera of the tribe Stigmoderini (Coleoptera: Buprestidae) a discussion of phylogenetic relationships
Anal tuberculosis. Report of a case
Gastric tuberculosis in the past and present
Adaptive responses of the cardiovascular system to prolonged spaceflight conditions: assessment with Holter monitoring

Serum epidermal growth factor concentration and tissue epidermal growth factor receptor content in relation to tyrosine kinase activity in human endometrial adenocarcinoma


Serum epidermal growth factor concentration and tissue epidermal growth factor receptor content in relation to tyrosine kinase activity in human endometrial adenocarcinoma



9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY Author The 9th International Congress of Immunology : 16




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 033359814

Download citation: RISBibTeXText

Related references

Epidermal growth factor receptor tyrosine kinase activity, tissue EGF-r and EGF concentrations in human endometrial adenocarcinoma. FASEB Journal 10(6): A1054, 1996

Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 39(3): 1010428317695939, 2017

Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. The Journal of Biological Chemistry 259(12): 7755-7760, 1984

Analogs of human epidermal growth factor which partially inhibit the growth factor-dependent protein-tyrosine kinase activity of the epidermal growth factor receptor. Febs Letters 264(1): 105-108, 1990

Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. Journal of Biological Chemistry 259(12): 7755-7760, 1984

Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors. ChemoTherapy 57(2): 108-114, 2011

Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?. Cancer Science 107(8): 1134-1140, 2016

Antibodies to the atp binding site of the human epidermal growth factor receptor as specific inhibitors of epidermal growth factor stimulated protein tyrosine kinase activity. European Journal of Biochemistry 158(2): 245-254, 1986

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. Cancer Science 105(8): 1040-1048, 2014

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). Journal of Medicinal Chemistry 46(1): 49-63, 2003

Epidermal growth factor receptor immunostaining and epidermal growth factor receptor-tyrosine kinase activity in proliferative and neoplastic human endometrium. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 21(6): 358-366, 2000

Epidermal Growth Factor Receptor Immunostaining and Epidermal Growth Factor Receptor-Tyrosine Kinase Activity in Proliferative and Neoplastic Human Endometriu M. Tumor Biology 21(6): 358-366, 2000

Estrogen Receptor β 1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors' Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma. Frontiers in Oncology 10: 603883, 2020

Chemotherapy should be performed in epidermal growth factor receptor mutation-positive lung adenocarcinoma patients who had progressive disease to the first epidermal growth factor receptor-tyrosine kinase inhibitor. Anti-Cancer Drugs 31(9): 959-965, 2020

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. Bmc Cancer 21(1): 52, 2021